| Gene symbol | USH2A | Synonyms | RP39, US2, USH2, dJ1111A8.1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q41 | dbXrefs | |
| Description | usherin | ||||
| GTO ID | GTC2037 |
| Trial ID | NCT03780257 |
| Disease | Retinitis Pigmentosa |
| Altered gene | USH2A |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | QR-421a|ultevursen |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene |
| Year | 2018 |
| Country | Canada|France|United States |
| Company sponsor | ProQR Therapeutics |
| Other ID(s) | PQ-421a-001|2018-002433-38 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||